



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Fumonisin B2-¹³C₃₄

Cat. No.:	HY-N6723S
CAS No.:	1217481-36-1
Molecular Formula:	¹³ C ₃₄ H ₅₉ NO ₁₄
Molecular Weight:	739.58
Target:	Isotope-Labeled Compounds
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Fumonisin B2- ¹³ C ₃₄ is the ¹³ C labeled Fumonisin B2 (HY-N6723) ^[1] . Fumonisin B2, a mycotoxin produced by Fusarium moniliforme in various grains, is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis ^{[2][3]} .
IC₅₀ & Target	Sphingosine N-acyltransferase ^[2]
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Henry MH, et al. The toxicity of fumonisin B1, B2, and B3, individually and in combination, in chicken embryos. *Poult Sci.* 2001 Apr;80(4):401-7.
- [2]. Wei T, et al. Natural occurrence of fumonisins B1 and B2 in corn in four provinces of China. *Food Addit Contam Part B Surveill.* 2013;6(4):270-4.
- [3]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019 Feb;53(2):211-220.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA